Abiopharma

QIAGEN announces adjustment of conversion price under its US$750,000,000 Convertible Bonds due 2032

QIAGEN announces adjustment of conversion price under its US$ 500,000,000 Convertible Bonds due 2027

QIAGEN announces adjustment of conversion price under its US$ 500,000,000 Convertible Bonds due 2031

Tentative approval of ANDA #ANDA #220284 for AMPHETAMINE. Decision date: 01/07/2026

Tentative approval of ANDA #ANDA #219687 for RIFAXIMIN. Decision date: 01/07/2026

📋 Matthijs Glastra (Officer) plans to sell 6K shares of Novanta Inc (at $130.00 each, total $803K) Filed: Jan 09, 2026 | ID: 001495

New Form 25-NSE/A - QIAGEN N.V. Filed: 2026-01-09 AccNo: 0000876661-26-000033 Size: 3 KB

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Siokas Grigorios 🟢 acquired 156.2K shares of Cosmos Health Inc. (COSM) at $0.52 Transaction Date: Jan 08, 2026 | Filing ID: 000116

New Form SCHEDULE 13D/A - Humacyte, Inc. Filed: 2026-01-09 AccNo: 0001104659-26-002371 Size: 13 KB

Tentative approval of ANDA #ANDA #220051 for SELENIOUS ACID. Decision date: 01/07/2026

New Form 3 - METTLER TOLEDO INTERNATIONAL INC/ Filed: 2026-01-09 AccNo: 0001037646-26-000003 Size: 11 KB

Tentative approval of ANDA #ANDA #220313 for GLYCEROL PHENYLBUTYRATE. Decision date: 01/07/2026

Tentative approval of ANDA #ANDA #219408 for DAPAGLIFLOZIN. Decision date: 01/08/2026